Curis, Inc. Stock News

Curis, Inc. (NASDAQ:CRIS ) Cantor Global Healthcare Conference 2025 September 5, 2025 9:45 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Conference Call Participants Li Wang Watsek - Cantor Fitzgerald & Co., Research Division Presentation Li Wang Watsek Research Analyst Hey, everyone. Welcome to our next session with Curis.

Curis, Inc. (NASDAQ:CRIS ) H.C. Wainwright 27th Annual Global Investment Conference September 10, 2025 10:00 AM EDT Company Participants James Dentzer - President, CEO, Secretary, Treasurer & Director Presentation James Dentzer President, CEO, Secretary, Treasurer & Director Good afternoon.

LEXINGTON, Mass. , Sept. 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that James Dentzer, President and Chief Executive Officer of Curis, will participate at the following conferences: The Cantor Global Healthcare Conference 2025 being held Sep...

Curis (CRIS 4.38%), a biotechnology company focused on developing targeted cancer therapies, reported its earnings for the second quarter of 2025 on August 5, 2025. Curis reported a GAAP net loss of $0.68 per share, outperforming the analyst expectation of a $1.36 GAAP loss.

Curis, Inc. (NASDAQ:CRIS ) Q2 2025 Earnings Conference Call August 5, 2025 8:30 AM ET Company Participants Ahmed M. Hamdy - Chief Medical Officer Diantha Duvall - CFO and Principal Financial & Accounting Officer James E.

Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass.

LEXINGTON, Mass. , July 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its second quarter 2025 financial and operating results on Tuesday, August 5, 2025, at 8:00 a.m.

LEXINGTON, Mass. , July 2, 2025 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that it has entered into a definitive agreement with a combination of existing and new investors for the purchase of 1,538,460 shares ("Shares") of its common stock ...